The prize was established in 2013 to help fund explorative and high-risk/high-reward cancer research in areas where traditional funding is often lacking.
MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.
The state of California has given the lab permission to start offering its QClamp test to screen for tumor oncogenic driver and resistance mutations in tumor DNA.